Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minzhilin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Minzhilin is a brand name for mizolastine extended-release tablets, a second-generation, non-sedating antihistamine. It is primarily used for the symptomatic relief of allergic conditions such as seasonal and perennial allergic rhinitis (hay fever) and urticaria. Its mechanism of action involves selectively blocking peripheral H1 receptors, thereby preventing histamine from binding and reducing allergic symptoms. It also exhibits mast-stabilizing and anti-inflammatory properties. Minzhilin is administered orally.
- Brand names
- MinzhilinMizollenMistamineZehistElinaMastelOriensZolimZolistamZolistan
- Other names
- mizolastine extended-release tablets咪唑斯汀缓释片皿治林
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Minzhilin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minzhilin.